Rabello Lígia Sarmet Cunha Farah, Pitrowsky Melissa Tassano, Soares Márcio, Póvoa Pedro, Salluh Jorge Ibrain Figueira
Rev Bras Ter Intensiva. 2011 Dec;23(4):499-506.
Community-acquired pneumonia (CAP) is the most common infectious disease requiring admission to intensive care units (ICUs), and achieving an early and precise diagnosis of CAP remains a challenge. Biomarkers play an important role in improving clinical judgment in the emergency room and are adjuvant in evaluating treatment responses. Novel biomarkers, such as cortisol, pro-adrenomedullin and endothelin-1, have been shown to be associated with disease severity and short-term outcomes. This review article focuses on the clinical use of novel biomarkers, severity prediction and treatment monitoring as well as future directions of the field.
社区获得性肺炎（CAP）是最常见的需要入住重症监护病房（ICU）的传染病，而实现CAP的早期准确诊断仍然是一项挑战。生物标志物在改善急诊室的临床判断中发挥着重要作用，并且在评估治疗反应方面具有辅助作用。新型生物标志物，如皮质醇、前肾上腺髓质素和内皮素-1，已被证明与疾病严重程度和短期预后相关。这篇综述文章重点关注新型生物标志物的临床应用、严重程度预测和治疗监测以及该领域的未来发展方向。
